0JQ2 Stock Overview
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
KALA BIO, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.83 |
52 Week High | US$18.76 |
52 Week Low | US$5.27 |
Beta | -1.84 |
1 Month Change | -14.48% |
3 Month Change | -4.55% |
1 Year Change | -54.95% |
3 Year Change | -97.90% |
5 Year Change | -98.33% |
Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Shareholder Returns
0JQ2 | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | 4.3% | 1.7% |
1Y | -55.0% | -26.1% | 1.4% |
Return vs Industry: 0JQ2 underperformed the UK Biotechs industry which returned -26.1% over the past year.
Return vs Market: 0JQ2 underperformed the UK Market which returned 1.4% over the past year.
Price Volatility
0JQ2 volatility | |
---|---|
0JQ2 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 7.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0JQ2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0JQ2's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 43 | Mark Iwicki | www.kalarx.com |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
KALA BIO, Inc. Fundamentals Summary
0JQ2 fundamental statistics | |
---|---|
Market cap | US$19.29m |
Earnings (TTM) | -US$42.20m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 0JQ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0JQ2 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$42.20m |
Earnings | -US$42.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -14.98 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 455.6% |
How did 0JQ2 perform over the long term?
See historical performance and comparison